Posted by Michael Wonder on 21 Jun 2023
Teikoku Pharma granted FDA fast track designation for TPU-006, a novel 4 day dexmedetomidine transdermal system for post operative pain management
21 June 2023 - Teikoku Pharma today announced that the US FDA granted fast track designation for TPU-006 in managing post-operative pain.
TPU-006 is an investigational 4 day dexmedetomidine transdermal system, a novel drug delivery technology with a non-opioid active moiety for managing post-surgical pain.
